Debt-to-equity of HALOZYME THERAPEUTICS, INC. from 30 Sep 2023 to 31 Dec 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: HALOZYME THERAPEUTICS, INC. quarterly Debt-to-equity in % history and change rate from 30 Sep 2023 to 31 Dec 2025.
HALOZYME THERAPEUTICS, INC. Debt-to-equity for the quarter ending 31 Dec 2025 was 558%, a 6.7% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

HALOZYME THERAPEUTICS, INC. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q4 2025	558%	+35%	+6.7%	31 Dec 2025
Q3 2025	407%	-256%	-39%	30 Sep 2025
Q2 2025	417%	-413%	-50%	30 Jun 2025
Q1 2025	426%	-574%	-57%	31 Mar 2025
Q4 2024	523%	-675%	-56%	31 Dec 2024
Q3 2024	663%	-376%	-36%	30 Sep 2024
Q2 2024	829%			30 Jun 2024
Q1 2024	1000%			31 Mar 2024
Q4 2023	1198%			31 Dec 2023
Q3 2023	1039%			30 Sep 2023

* An asterisk sign (*) next to the value indicates that the value is likely invalid.